Clinical Cancer Research: 18 (9)

Highlights

Highlights

Highlights of This Issue

Clin Cancer Res May 1 2012 18 (9) 2415-2415;

CCR Translations

CCR Translations

For Breast Cancer Prognosis, Immunoglobulin Kappa Chain Surfaces to the Top

Theresa L. Whiteside and Soldano Ferrone

Clin Cancer Res May 1 2012 18 (9) 2417-2419; DOI:10.1158/1078-0432.CCR-12-0566
CCR Translations

Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?

Federica Catalanotti and David B. Solit

Clin Cancer Res May 1 2012 18 (9) 2420-2422; DOI:10.1158/1078-0432.CCR-12-0626

CCR New Strategies

CCR New Strategies

New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome

Kristina A. Cole and John M. Maris

Clin Cancer Res May 1 2012 18 (9) 2423-2428; DOI:10.1158/1078-0432.CCR-11-1409

Molecular Pathways

Molecular Pathways

Molecular Pathways: The Role of Primary Cilia in Cancer Progression and Therapeutics with a Focus on Hedgehog Signaling

Nadia B. Hassounah, Thomas A. Bunch and Kimberly M. McDermott

Clin Cancer Res May 1 2012 18 (9) 2429-2435; DOI:10.1158/1078-0432.CCR-11-0755
Molecular Pathways

Molecular Pathways: Old Drugs Define New Pathways: Non-Histone Acetylation at the Crossroads of the DNA Damage Response and Autophagy

Oronza Antonietta Botrugno, Thomas Robert, Fabio Vanoli, Marco Foiani and Saverio Minucci

Clin Cancer Res May 1 2012 18 (9) 2436-2442; DOI:10.1158/1078-0432.CCR-11-0767

Review

Review

Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities

Pablo Perez-Moreno, Elisabeth Brambilla, Roman Thomas and Jean-Charles Soria

Clin Cancer Res May 1 2012 18 (9) 2443-2451; DOI:10.1158/1078-0432.CCR-11-2370

Human Cancer Biology

Human Cancer Biology

Upregulated JAG1 Enhances Cell Proliferation in Adrenocortical Carcinoma

Derek P. Simon, Thomas J. Giordano and Gary D. Hammer

Clin Cancer Res May 1 2012 18 (9) 2452-2464; DOI:10.1158/1078-0432.CCR-11-2371
Human Cancer Biology

Detection and Characterization of a Novel Subset of CD8⁺CD57⁺ T Cells in Metastatic Melanoma with an Incompletely Differentiated Phenotype

Richard C. Wu, Shujuan Liu, Jessica A. Chacon, Sheng Wu, Yufeng Li, Pariya Sukhumalchandra, James L. Murray, Jeffrey J. Molldrem, Patrick Hwu, Hanspeter Pircher, Gregory Lizée and Laszlo G. Radvanyi

Clin Cancer Res May 1 2012 18 (9) 2465-2477; DOI:10.1158/1078-0432.CCR-11-2034
Human Cancer Biology

Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients

Elliot L. Servais, Christos Colovos, Luis Rodriguez, Adam J. Bograd, Jun-ichi Nitadori, Camelia Sima, Valerie W. Rusch, Michel Sadelain and Prasad S. Adusumilli

Clin Cancer Res May 1 2012 18 (9) 2478-2489; DOI:10.1158/1078-0432.CCR-11-2614
Human Cancer Biology

IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma

Daniel Gorovets, Kasthuri Kannan, Ronglai Shen, Edward R. Kastenhuber, Nasrin Islamdoust, Carl Campos, Elena Pentsova, Adriana Heguy, Suresh C. Jhanwar, Ingo K. Mellinghoff, Timothy A. Chan and Jason T. Huse

Clin Cancer Res May 1 2012 18 (9) 2490-2501; DOI:10.1158/1078-0432.CCR-11-2977

Cancer Therapy: Preclinical

Cancer Therapy: Preclinical

The HSP90 Inhibitor XL888 Overcomes BRAF Inhibitor Resistance Mediated through Diverse Mechanisms

Kim H.T. Paraiso, H. Eirik Haarberg, Elizabeth Wood, Vito W. Rebecca, Y. Ann Chen, Yun Xiang, Antoni Ribas, Roger S. Lo, Jeffrey S. Weber, Vernon K. Sondak, Jobin K. John, Amod A. Sarnaik, John M. Koomen and Keiran S.M. Smalley

Clin Cancer Res May 1 2012 18 (9) 2502-2514; DOI:10.1158/1078-0432.CCR-11-2612
Cancer Therapy: Preclinical | Free Article

Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas

Giorgia Migliardi, Francesco Sassi, Davide Torti, Francesco Galimi, Eugenia R. Zanella, Michela Buscarino, Dario Ribero, Andrea Muratore, Paolo Massucco, Alberto Pisacane, Mauro Risio, Lorenzo Capussotti, Silvia Marsoni, Federica Di Nicolantonio, Alberto Bardelli, Paolo M. Comoglio, Livio Trusolino and Andrea Bertotti

Clin Cancer Res May 1 2012 18 (9) 2515-2525; DOI:10.1158/1078-0432.CCR-11-2683
Cancer Therapy: Preclinical

Spleen Cells from Young but Not Old Immunized Mice Eradicate Large Established Cancers

Karin Schreiber, Ainhoa Arina, Boris Engels, Michael T. Spiotto, John Sidney, Alessandro Sette, Theodore G. Karrison, Ralph R. Weichselbaum, Donald A. Rowley and Hans Schreiber

Clin Cancer Res May 1 2012 18 (9) 2526-2533; DOI:10.1158/1078-0432.CCR-12-0127
Cancer Therapy: Preclinical

Akt Inhibitors MK-2206 and Nelfinavir Overcome mTOR Inhibitor Resistance in Diffuse Large B-cell Lymphoma

Adam M. Petrich, Violetta Leshchenko, Pei-Yu Kuo, Bing Xia, Venu K. Thirukonda, Netha Ulahannan, Shanisha Gordon, Melissa J. Fazzari, B. Hilda Ye, Joseph A. Sparano and Samir Parekh

Clin Cancer Res May 1 2012 18 (9) 2534-2544; DOI:10.1158/1078-0432.CCR-11-1407
Cancer Therapy: Preclinical

Survivin Is a Viable Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors

Markus P. Ghadimi, Eric D. Young, Roman Belousov, Yiqun Zhang, Gonzalo Lopez, Kristelle Lusby, Christine Kivlin, Elizabeth G. Demicco, Chad J. Creighton, Alexander J. Lazar, Raphael E. Pollock and Dina Lev

Clin Cancer Res May 1 2012 18 (9) 2545-2557; DOI:10.1158/1078-0432.CCR-11-2592
Cancer Therapy: Preclinical

mTOR as a Molecular Target in HPV-Associated Oral and Cervical Squamous Carcinomas

Alfredo A. Molinolo, Christina Marsh, Mohamed El Dinali, Nitin Gangane, Kaitlin Jennison, Stephen Hewitt, Vyomesh Patel, Tanguy Y. Seiwert and J. Silvio Gutkind

Clin Cancer Res May 1 2012 18 (9) 2558-2568; DOI:10.1158/1078-0432.CCR-11-2824
Cancer Therapy: Preclinical

Peptides Mimicking the Unique ARTS-XIAP Binding Site Promote Apoptotic Cell Death in Cultured Cancer Cells

Natalia Edison, Tali-Haviv Reingewertz, Yossi Gottfried, Tali Lev, Dotan Zuri, Inbal Maniv, Marie-Jeanne Carp, Gil Shalev, Assaf Friedler and Sarit Larisch

Clin Cancer Res May 1 2012 18 (9) 2569-2578; DOI:10.1158/1078-0432.CCR-11-1430
Cancer Therapy: Preclinical

Preferential Replication of Systemically Delivered Oncolytic Vaccinia Virus in Focally Irradiated Glioma Xenografts

Sunil J. Advani, Lisa Buckel, Nanhai G. Chen, Daniel J. Scanderbeg, Ulrike Geissinger, Qian Zhang, Yong A. Yu, Richard J. Aguilar, Arno J. Mundt and Aladar A. Szalay

Clin Cancer Res May 1 2012 18 (9) 2579-2590; DOI:10.1158/1078-0432.CCR-11-2394
Cancer Therapy: Preclinical

Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts

Mark D. Walsh, Suzan K. Hanna, Jeremy Sen, Sumit Rawal, Carolina B. Cabral, Alex V. Yurkovetskiy, Robert J. Fram, Timothy B. Lowinger and William C. Zamboni

Clin Cancer Res May 1 2012 18 (9) 2591-2602; DOI:10.1158/1078-0432.CCR-11-1554
Cancer Therapy: Preclinical

Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy

Celina García-García, Yasir H. Ibrahim, Violeta Serra, Maria Teresa Calvo, Marta Guzmán, Judit Grueso, Claudia Aura, José Pérez, Katti Jessen, Yi Liu, Christian Rommel, Josep Tabernero, José Baselga and Maurizio Scaltriti

Clin Cancer Res May 1 2012 18 (9) 2603-2612; DOI:10.1158/1078-0432.CCR-11-2750

Imaging, Diagnosis, Prognosis

Imaging, Diagnosis, Prognosis

Proximal Fluid Proteome Profiling of Mouse Colon Tumors Reveals Biomarkers for Early Diagnosis of Human Colorectal Cancer

Remond J.A. Fijneman, Meike de Wit, Maral Pourghiasian, Sander R. Piersma, Thang V. Pham, Marc O. Warmoes, Mehrdad Lavaei, Chloe Piso, Fiona Smit, Pien M. Delis-van Diemen, Sietze T. van Turenhout, Jochim S. Terhaar sive Droste, Chris J.J. Mulder, Marinus A. Blankenstein, Els C. Robanus-Maandag, Ron Smits, Riccardo Fodde, Victor W.M. van Hinsbergh, Gerrit A. Meijer and Connie R. Jimenez

Clin Cancer Res May 1 2012 18 (9) 2613-2624; DOI:10.1158/1078-0432.CCR-11-1937

Cancer Therapy: Clinical

Cancer Therapy: Clinical

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

Aung Naing, Patricia LoRusso, Siqing Fu, David S. Hong, Pete Anderson, Robert S. Benjamin, Joseph Ludwig, Helen X. Chen, Laurence A. Doyle and Razelle Kurzrock

Clin Cancer Res May 1 2012 18 (9) 2625-2631; DOI:10.1158/1078-0432.CCR-12-0061
Cancer Therapy: Clinical

Requirements to Assess Feasibility of Phase 0 Trials during Major Abdominal Surgery: Variability of PARP Activity

Florian Heitz, Andreas du Bois, Justine Rochon, Stefanie Scheil-Bertram, Rita Hils, Annette Fisseler-Eckhoff, Jana Barinoff, Christine Kaub and Philipp Harter

Clin Cancer Res May 1 2012 18 (9) 2632-2637; DOI:10.1158/1078-0432.CCR-12-0021
Cancer Therapy: Clinical

The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial

Jason J. Luke, David R. D'Adamo, Mark A. Dickson, Mary Louise Keohan, Richard D. Carvajal, Robert G. Maki, Elisa de Stanchina, Elgilda Musi, Samuel Singer and Gary K. Schwartz

Clin Cancer Res May 1 2012 18 (9) 2638-2647; DOI:10.1158/1078-0432.CCR-11-3203
Cancer Therapy: Clinical

Denosumab Dose Selection for Patients with Bone Metastases from Solid Tumors

Sameer Doshi, Liviawati Sutjandra, Jenny Zheng, Winnie Sohn, Mark Peterson, Graham Jang, Andrew T. Chow and Juan Jose Pérez-Ruixo

Clin Cancer Res May 1 2012 18 (9) 2648-2657; DOI:10.1158/1078-0432.CCR-11-2944
Cancer Therapy: Clinical

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Klaus Mross, Annette Frost, Simone Steinbild, Susanne Hedbom, Martin Büchert, Ulrike Fasol, Clemens Unger, Jörn Krätzschmar, Roland Heinig, Oliver Boix and Olaf Christensen

Clin Cancer Res May 1 2012 18 (9) 2658-2667; DOI:10.1158/1078-0432.CCR-11-1900
Cancer Therapy: Clinical

Phase I Trial of Intraperitoneal Pemetrexed, Cisplatin, and Paclitaxel in Optimally Debulked Ovarian Cancer

Setsuko K. Chambers, H-H. Sherry Chow, Mike F. Janicek, Janiel M. Cragun, Kenneth D. Hatch, Haiyan Cui, Cynthia Laughren, Mary C. Clouser, Janice L. Cohen, Heather M. Wright, Nisreen Abu Shahin and David S. Alberts

Clin Cancer Res May 1 2012 18 (9) 2668-2678; DOI:10.1158/1078-0432.CCR-12-0261
Cancer Therapy: Clinical

Phase I Study of Vincristine, Irinotecan, and ¹³¹I-Metaiodobenzylguanidine for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial

Steven G. DuBois, Louis Chesler, Susan Groshen, Randall Hawkins, Fariba Goodarzian, Hiroyuki Shimada, Greg Yanik, Michael Tagen, Clinton Stewart, Yael P. Mosse, John M. Maris, Denice Tsao-Wei, Araz Marachelian, Judith G. Villablanca and Katherine K. Matthay

Clin Cancer Res May 1 2012 18 (9) 2679-2686; DOI:10.1158/1078-0432.CCR-11-3201
Cancer Therapy: Clinical

A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

Udai Banerji, Leni van Doorn, Dionysis Papadatos-Pastos, Rebecca Kristeleit, Phillip Debnam, Matthew Tall, Adam Stewart, Florence Raynaud, Michelle Dawn Garrett, Martin Toal, Leon Hooftman, Johann Sebastian De Bono, Jaap Verweij and Ferry ALM Eskens

Clin Cancer Res May 1 2012 18 (9) 2687-2694; DOI:10.1158/1078-0432.CCR-11-3165

Predictive Biomarkers and Personalized Medicine

Predictive Biomarkers and Personalized Medicine

A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin κ C as a Compatible Prognostic Marker in Human Solid Tumors

Marcus Schmidt, Birte Hellwig, Seddik Hammad, Amnah Othman, Miriam Lohr, Zonglin Chen, Daniel Boehm, Susanne Gebhard, Ilka Petry, Antje Lebrecht, Cristina Cadenas, Rosemarie Marchan, Joanna D. Stewart, Christine Solbach, Lars Holmberg, Karolina Edlund, Hanna Göransson Kultima, Achim Rody, Anders Berglund, Mats Lambe, Anders Isaksson, Johan Botling, Thomas Karn, Volkmar Müller, Aslihan Gerhold-Ay, Christina Cotarelo, Martin Sebastian, Ralf Kronenwett, Hans Bojar, Hans-Anton Lehr, Ugur Sahin, Heinz Koelbl, Mathias Gehrmann, Patrick Micke, Jörg Rahnenführer and Jan G. Hengstler

Clin Cancer Res May 1 2012 18 (9) 2695-2703; DOI:10.1158/1078-0432.CCR-11-2210
Predictive Biomarkers and Personalized Medicine

Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib

John J. Arcaroli, Kevin S. Quackenbush, Rebecca W. Powell, Todd M. Pitts, Anna Spreafico, Marileila Varella-Garcia, Lynne Bemis, Aik Choon Tan, Jaclyn M. Reinemann, Basel M. Touban, Arvind Dasari, S. Gail Eckhardt and Wells A. Messersmith

Clin Cancer Res May 1 2012 18 (9) 2704-2714; DOI:10.1158/1078-0432.CCR-11-3167

Letters to the Editor

Letters to the Editor

Population Pharmacokinetics of Busulfan in Children–Letter

Laurent Nguyen, Angelo Paci and Gilles Vassal

Clin Cancer Res May 1 2012 18 (9) 2715-2716; DOI:10.1158/1078-0432.CCR-11-3297
Letters to the Editor

Population Pharmacokinetics of Busulfan in Children–Response

Mirjam N. Trame, Martin Bergstrand, Mats O. Karlsson and Georg Hempel

Clin Cancer Res May 1 2012 18 (9) 2717-2718; DOI:10.1158/1078-0432.CCR-12-0425

Corrections

Corrections

Correction: Pancreatic Tumor Suppression by Benzyl Isothiocyanate Is Associated with Inhibition of PI3K/AKT/FOXO Pathway

Clin Cancer Res May 1 2012 18 (9) 2719-2719; DOI:10.1158/1078-0432.CCR-12-0772
Corrections

Correction: PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy

Clin Cancer Res May 1 2012 18 (9) 2720-2720; DOI:10.1158/1078-0432.CCR-12-0960

Main menu

User menu

Search

Table of Contents

Highlights

CCR Translations

CCR New Strategies

Molecular Pathways

Review

Human Cancer Biology

Cancer Therapy: Preclinical

Imaging, Diagnosis, Prognosis

Cancer Therapy: Clinical

Predictive Biomarkers and Personalized Medicine

Letters to the Editor

Corrections

Issue Highlights

Jump to

Articles

Info for

About Clinical Cancer Research